Alantra advised Biotay on its sale to Phibro Animal Health Corporation
Alantra advised the shareholders of Biotay S.A. on the sale of 100% of the shares to Phibro Animal Health Corporation.
Biotay is a leading animal health and nutritional products company founded in 1985 by former management of Eli Lilly & Co. in Argentina, engaged in production, marketing and distribution of products in Argentina and Uruguay. The company specializes in the bovine cattle, swine and poultry segments, and to a lesser extent horses and other species.
Juan Carlos Repetto, Biotay’s Chief Executive Officer, said in a recent public statement: “We are excited and looking forward to leveraging the strengths of both organizations and resources to better serve our customers, Phibro’s proven expertise and innovative platforms will provide strategic resources to maximize Biotay’s customer service capabilities, providing our customers with increased animal health, productivity and nutrition quality while improving animal welfare.”
The company owns an industrial plant and commercial offices in Argentina. The product portfolio consists of over 300 SKUs (Stock Keeping Unit), with approx. 600 clients. Biotay exports its products through representatives to more than six countries, mainly Uruguay, Bolivia and Paraguay.
Phibro is a global developer, manufacturer and marketer of animal health and mineral nutrition products for the poultry, swine, dairy, cattle and aquaculture markets. PAHC’s revenues and EBITDA reached US$764m and US$150m in LTM through June-2017, respectively. Market cap at the date of the transaction was US$1.34bn.
Jan 2020Buy-side advisoryJan 2020SECTOR HealthcareService M&A
Dec 2019Debt financingDec 2019SECTOR HealthcareService Debt Advisory
Oct 2019Buy-side advisoryValue $10.4 millionOct 2019SECTOR HealthcareService M&AValue $10.4 million
Sep 2019Buy-side advisorySep 2019SECTOR HealthcareService Debt Advisory